Enzalutamide in Combination With PSA-TRICOM in Patients With Non-Metastatic Castration Sensitive Prostate Cancer

NCT01875250 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

38

Enrollment

NIH

Sponsor class

Conditions

Prostate Cancer

Interventions

BIOLOGICAL: PROSTVAC-F (Fowlpox)/TRICOM
BIOLOGICAL: PROSTVAC-V (Vaccinia)/TRICOM
DRUG: Enzalutamide (Xtandi)

Sponsor

National Cancer Institute (NCI)